Two Very Different Flavors Of Ocular Gene Therapy Get A Boost
• By Mark Ratner
The 2021 collaboration between Abbvie and Regenxbio to develop an anti-VEGF gene therapy for chronic retinal diseases is a noteworthy deal in the gene therapy space. But for both clinical and commercial reasons, it is a one-off opportunity and not an indicator of the overall potential of gene therapies to address eye diseases. Interest in optogenetics, however, which is the introduction of light-sensing genes into cells in the eye to restore vison, may be on the rise.
• Source: Alamy
The first thing that comes to mind when thinking about gene therapy is its ability to replace a missing gene or correct a defective one. A gene therapy vector can also be used to insert instructions for cells to begin making a therapeutic protein. Regenxbio Inc.’s RGX-314, which uses an adeno-associated virus (AAV) vector to deliver an inhibitor of vascular endothelial growth factor (VEGF), is one such example.
In a move to boost its eye care portfolio following the acquisition of Allergan plc, AbbVie Inc. licensed...
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.